PGEN

Precigen, Inc.

Approval Confirmed

PAPZIMEOS

Recurrent Respiratory Papillomatosis (RRP)

Resolved

340days ago

Approval decision · Aug 1, 2025

What's at stake A final FDA approval decision on PAPZIMEOS for Recurrent Respiratory Papillomatosis (RRP) is expected Aug 1, 2025.

Primary source · SEC 8-K verified 15h ago

“In August 2025, the US Food and Drug Administration (FDA) granted full approval of PAPZIMEOS with a broad label for the treatment of adults with RRP.”

Add to calendar Post on X Reddit

Provenance